Top

Published in:

01-05-2020 | Mastectomy | Clinical trial

Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients

Authors: Antônio Luiz Frasson, Martina Lichtenfels, Alessandra Anton Borba de Souza, Betina Vollbrecht, Ana Beatriz Falcone, Mônica Adriana Rodriguez Martinez Frasson, Fernanda Barbosa

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Abstract

Purpose

Women with mutations in breast cancer predisposition genes have a significantly higher lifetime risk of developing breast cancer and can opt for risk-reducing mastectomy. Women with positive family history of cancer can also opt for prophylactic surgery as a preventive method in selected cases. Current studies showed reduced risk of developing breast cancer after prophylactic nipple-sparing mastectomy, however, despite the good clinical outcomes, one of the main concerns regarding nipple-sparing mastectomy (NSM) is the oncological safety of nipple-areola complex preservation. In this study, we aimed to evaluate the indications, complication rates, and unfavorable events of 62 Brazilian patients that underwent risk-reducing NSM from 2004 to 2018.

Methods

Patient data were reviewed retrospectively and descriptive statistics were utilized to summarize the findings.

Results

The mean patients age was 43.8 years. The main indication for risk-reducing NSM was the presence of pathogenic mutation (53.3%), followed by atypia or lobular carcinoma in situ (25.8), and family history of breast cancer and/or ovarian cancer (20.9%). There were four (3.2%) incidental diagnosis of ductal carcinoma in situ and one invasive ductal carcinoma (0.8%). From the 124 prophylactic NSM performed, two (1.6%) complications had occurred: one (0.8%) infection and one (0.8%) partial nipple necrosis. In a mean follow-up of 50 months, there was one (1.6%) newly diagnosed breast cancer in the 62 patients undergoing prophylactic NSM.

Conclusions

Our findings demonstrated efficacy and safety to perform NSM as prophylactic surgery with good oncological outcomes and low complication rates in a case series of Brazilian patients.

Narod SA (2010) BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 7(12):702–707. https://doi.org/10.1038/nrclinonc.2010.166 CrossRefPubMed

Castera L, Krieger S, Rousselin A et al (2014) Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet 22:1305–1313. https://doi.org/10.1038/ejhg.2014.16 CrossRefPubMedPubMedCentral

Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112 CrossRefPubMed

Dull B, Conant L, Myckatyn T et al (2017) Nipple-sparing mastectomies: Clinical outcomes from a single academic institution. Mol Clin Oncol 6:737–742. https://doi.org/10.3892/mco.2017.1208 CrossRefPubMedPubMedCentral

Smith BL, Tang R, Rai U et al (2017) Oncologic safety of nipple-sparing mastectomy in women with breast cancer. J Am Coll Surg 225(3):361–365. https://doi.org/10.1016/j.jamcollsurg.2017.06.013 CrossRefPubMed

Liede A, Cai M, Crouter TF et al (2018) Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect. Breast Cancer Res Treat 171(2):435–442. https://doi.org/10.1007/s10549-018-4824-9 CrossRefPubMedPubMedCentral

Isaksson K, Arver B, Bottai M et al (2019) Bilateral risk-reducing mastectomies with implant-based reconstructions followed long term: a consecutive series of 185 patients. World J Surg 43:2262–2270. https://doi.org/10.1007/s00268-019-05037-4 CrossRefPubMed

Manning AT, Wood C, Eaton A et al (2015) Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance. Br J Surg 102(11):1354–1359. https://doi.org/10.1002/bjs.9884 CrossRefPubMedPubMedCentral

Tondu T, Thiessen F, Tjalma WA (2016) Prophylatic bilateral Nipple-sparing mastectomy ans a staged breast reconstruction technique: preliminar results. Breast Cancer 10:185–189. https://doi.org/10.4137/BCBCR.S40033 CrossRefPubMed

10.

Muller T, Baratte A, Bruant-Rodier C et al (2018) Oncological safety of nipple-sparing prophylactic mastectomy: a review of the literature on 3716 cases. Ann Chir Plast Esthet 63(3):e6–e13. https://doi.org/10.1016/j.anplas.2017.09.005 CrossRefPubMed

11.

Jakub JW, Peled AW, Gray RJ et al (2018) Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA 153(2):123–129. https://doi.org/10.1001/jamasurg.2017.3422 CrossRef

12.

Muller T, Baratte A, Bruant-Roider C et al (2018) Oncological safety of nipple-sparing prophylactic mastectomy: a review of the literature on 3716 cases. Ann Chir Plast Esthet 63(3):e6–e13. https://doi.org/10.1016/j.anplas.2017.09.005 CrossRefPubMed

13.

Grobmyer SR, Pederson HJ, Valente SA (2018) Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy. BJS Open 3(2):169–173. https://doi.org/10.1002/bjs5.50117 CrossRefPubMedPubMedCentral

14.

Wu ZY, Kim HJ, Lee JW et al (2019) Breast cancer recurrence in the nipple-areola complex after nipple-sparing mastectomy with immediate breast reconstruction for invasive breast cancer. JAMA Surg. https://doi.org/10.1001/jamasurg.2019.2959 CrossRefPubMedPubMedCentral

15.

Eisemann BS, Spiegel AJ (2018) Mastectomy and breast reconstruction: indications and evidence for current management strategies. Clin Plast Surg 45:129–136. https://doi.org/10.1016/j.cps.2017.08.013 CrossRefPubMed

16.

Henry DA, Lee MC, Almanza D et al (2019) Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE). Breast Cancer Res Treat 174(1):39–45. https://doi.org/10.1007/s10549-018-5057 CrossRefPubMed

17.

Beitsch PD, Whitworth PW, Hughes K et al (2019) Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37(6):453–460. https://doi.org/10.1200/JCO.18.01631 CrossRefPubMed

18.

Graffeo R, Livraghi L, Pagani O et al (2016) Time too incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat 160(3):393–410. https://doi.org/10.1007/s10549-016-4003-9 CrossRefPubMed

19.

Henry DA, Lee MC, Almanza D et al (2019) Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndroms in the Inherited Cancer Registry (ICARE). Breast Cancer Res Treat 174(1):39–45. https://doi.org/10.1007/s10549-018-5057-7 CrossRefPubMed

20.

Mau C, Untch M (2017) Prophylactic surgey: for whom, when and how? Breast Care 12(6):379–384. https://doi.org/10.1159/000485830 CrossRefPubMedPubMedCentral

21.

Nelson HD, Pappas M, Cantor A et al (2019) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: Update evidence reports and systemic review for the US preventive services task force. JAMA. 332(7):666–685. https://doi.org/10.1001/jama.2019.8430 CrossRef

22.

Hermel DJ, Wood ME, Chun J et al (2017) Multi-institutional evaluation of women at high risk of developing breast cancer. Clin Breast Cancer 17(6):427–432. https://doi.org/10.1016/j.clbc.2017.04.005 CrossRefPubMed

23.

Gilbert E, Zabor EC, Stempel M et al (2017) Differences among a modern cohort of BRCA mutation carriers choosing bilateral prophylactic mastectomies compared to breast surveillance. Am Surg Oncol 24:3048–3054. https://doi.org/10.1245/s10434-017-5976-2 CrossRef

24.

De Felice F, Marchetti C, Musella A et al (2015) Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol 22:2876–2880. https://doi.org/10.1245/s10434-015-4532-1 CrossRefPubMed

25.

Yao K, Liederbach E, Tang R et al (2015) Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol 22:370–376. https://doi.org/10.1245/s10434-014-3883-3 CrossRefPubMed

26.

Lai HW, Chen ST, Tai CM et al (2020) Robotic- versus Endoscopic-assisted nipple-sparing mastectomy with immediate prosthesis breast reconstruction in the management of breast cancer: a case-control comparison study with analysis of clinical outcomes, learning curve, patient-reported aesthetic results, and medical cost. Ann Surg Oncol. https://doi.org/10.1245/s10434-020-08223-0 CrossRefPubMed

27.

Lai HW, Toesca A, Sarfari B et al (2020) Consensus statement on robotic mastectomy-expert panel from international endoscopic and robotic breast surgery symposium (IERBS) 2019. Ann Surg. https://doi.org/10.1097/SLA.0000000000003789 CrossRefPubMed

28.

Sarfari B, Leymarie N, Honart JF et al (2018) Robotic prophylactic nipple-sparing mastectomy with immediate prosthetic breast reconstruction: a prospective study. Ann Surg Oncol 25(9):2579–2586. https://doi.org/10.1245/s10434-018-6555-x CrossRef

29.

Houvenaeghel G, Marie B, Rua S et al (2019) Robotic breast and reconstructive surgery: 100 procedures in 2-years for 80 patients. Surg Oncol 31:38–45. https://doi.org/10.1016/j.suronc.2019.09.005 CrossRefPubMed

30.

Maruccia M, Elia R, Gurrado A et al (2020) Skin-reducing mastectomy and pre-pectoral breast reconstruction in large ptotic breasts. Aesth Plast Surg. https://doi.org/10.1007/s00266-020-01616-2 CrossRef

31.

Vidya R, Iqbal FM, Becker H, Zhadan O (2019) World J Plast Surg 8(3):311–315. https://doi.org/10.29252/wjps.8.3.311 CrossRefPubMedPubMedCentral

32.

Khajuria A, Prokopenko M, Greenfield M et al (2019) A meta-analysis of clinical, patient-reported outcomes and cost of DIEP versus implant-based breast reconstruction. Plast Reconstr Surg Glob Open 7(10):e2486CrossRef

33.

Wade RG, Razzano S, Sassoon EM et al (2017) Complications in DIEP flap breast reconstruction after mastectomy for breast cancer: a prospective cohort study comparing unilateral versus bilateral reconstructions. Ann Surg Oncol 24(6):1465–1474. https://doi.org/10.1245/s10434-017-5807-5 CrossRefPubMed

Title: Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients
Authors: Antônio Luiz Frasson
Martina Lichtenfels
Alessandra Anton Borba de Souza
Betina Vollbrecht
Ana Beatriz Falcone
Mônica Adriana Rodriguez Martinez Frasson
Fernanda Barbosa
Publication date: 01-05-2020
Publisher: Springer US
Keywords: Mastectomy
Breast Cancer
Ovarian Cancer
Ovarian Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05582-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial

Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors

A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience

The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer

Behavior of metastatic breast cancer according to subtype

Keynote webinar | Spotlight on antibody–drug conjugates in cancer